Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma

Klinische Padiatrie

Volumn 224, Issue 3, 2012, Pages 139-142

  Bochennek, K ^a   Esser, R ^a   Lehrnbecher, T ^a   Glienke, W ^a   Wehner, S ^a   Erben, S ^a   Soerensen, J ^a   Schwabe, D ^a   Bader, P ^a   Klingebiel, T ^a   Koehl, U ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Hochrisiko Neuroblastom; Knochenmark; minimale Resterkrankung; Stammzelltransplantation

Indexed keywords

TYROSINE 3 MONOOXYGENASE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER MORPHOLOGY; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TYROSINE 3-MONOOXYGENASE; YOUNG ADULT;

EID: 84860553795     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0031-1301334     Document Type: Article

References (17)

1. Avigad S, Shukla S, Naumov I et al. Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma. Pediatr Blood Cancer: 2009; 53 1023 1028
2. Bader P, Hancock J, Kreyenberg H et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia: 2002; 16 1668 1672
3. Brodeur G M, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol: 1993; 11 1466 1477 (Pubitemid 23228250)
4. Burchill S A, Kinsey S E, Picton S et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol: 2001; 36 213 219
5. Cai J Y, Tang Y J, Jiang L M et al. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer: 2007; 49 952 957
6. Cheung I Y, Lo Piccolo M S, Kushner B H et al. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol: 2003; 21 3853 3858 (Pubitemid 46606241)
7. Corrias M V, Haupt R, Carlini B et al. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res: 2006; 12 5680 5685 (Pubitemid 44629595)
8. Esser R, Glienke W, Bochennek K et al. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and RT-PCR for tyrosine hydroxylase using both conventional and real-time PCR. Klin Padiatr: 2011; 223 326 331
9. Handgretinger R, Leung W, Ihm K et al. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? Br J Cancer: 2003; 88 1874 1877 (Pubitemid 36829661)
10. Hero B, Hunneman D H, Gahr M et al. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol: 2001; 36 220 223
11. Horibe K, Fukuda M, Miyajima Y et al. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol: 2001; 36 203 204
12. Koehl U, Bochennek K, Esser R et al. ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56 + CD3 NK cells. Int J Hematol: 2008; 87 98 105
13. Marabelle A, Merlin E, Halle P et al. CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma. Pediatr Blood Cancer: 2011; 56 134 142
14. Seeger R C, Reynolds C P, Gallego R et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol: 2000; 18 4067 4076 (Pubitemid 32038399)
15. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L et al. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem: 2009; 55 1316 1326
16. Trager C, Vernby A, Kullman A et al. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer: 2008; 123 2849 2855
17. Wehner S, Soerensen J, Schwabe D et al. 10-Parameter flow cytometry as a new tool to improve diagnosis and MRD follow-up of acute leukemias. Klin Padiatr: 2009; 221 393 395